Company news
Nexgel, Inc (NASDAQ:NXGL) news
Nexgel, Inc news releases on 6ix. Latest, Sep 23, 2026: NEXGEL Announces Dial-In Details for Investor Update Call
Press releases & updates
NEXGEL Announces Dial-In Details for Investor Update Call
September 23, 2026
NEXGEL Announces Date for Investor Update Call
September 16, 2026
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
August 20, 2026
NEXGEL Reports Second Quarter 2026 Financial Results
August 17, 2026
NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
June 3, 2026
NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration
May 18, 2026
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
May 13, 2026
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
May 12, 2026
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
May 5, 2026
NEXGEL Appoints Ian Blackman as Chief Financial Officer
April 27, 2026
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
April 21, 2026
Celularity Announces Closing of Transaction with NexGel
April 21, 2026
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
April 17, 2026
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
April 15, 2026
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
April 7, 2026
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
March 30, 2026
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
March 25, 2026
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
March 11, 2026
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
March 9, 2026
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence
February 10, 2026
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor
December 16, 2025
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
December 11, 2025
NEXGEL Reports Third Quarter 2025 Financial Results
November 11, 2025
NEXGEL to Report Third Quarter 2025 Financial Results on November 11th
November 3, 2025
NEXGEL to Present at the LD Micro Main Event XIX Conference on October 19-21
October 9, 2025
NEXGEL Reports Second Quarter 2025 Financial Results
August 12, 2025
NEXGEL to Report Second Quarter 2025 Financial Results on August 12th
August 6, 2025
NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors
August 5, 2025
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement
August 1, 2025
NEXGEL and STADA AG Announce Expansion of Partnership for North America
July 14, 2025
NEXGEL to Participate in the 6th Annual CEO Networking Event Hosted by Semco Capital on June 2nd
May 21, 2025
NEXGEL Reports First Quarter 2025 Financial Results
May 13, 2025
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
May 9, 2025
NEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24th
April 7, 2025
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
March 24, 2025
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
March 19, 2025
NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 25-26th, 2025
March 13, 2025
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
January 1, 2025
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
November 12, 2024
NEXGEL Announces $2,000,000 Registered Direct Offering
November 10, 2024
NEXGEL Preannounces Expected Record Third Quarter 2024 Revenue of $2.85 Million, an Increase of Approximately 133% Year-Over-Year and 98% Sequentially
October 9, 2024
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
October 3, 2024
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
August 13, 2024
NEXGEL Announces $1,110,000 Registered Direct Offering Led by Insiders
August 11, 2024
NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal
July 17, 2024
NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively
July 7, 2024
NEXGEL Subsidiary, CG Converting and Packaging, Announces it will Supply SilverSeal to Cintas Corporation
June 26, 2024
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
June 10, 2024
NEXGEL Acquires International Beauty Brand, Silly George
May 15, 2024
NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year
May 12, 2024